ExoLab Italy, a L’Aquila, Italy-based biotech startup specializing within the creation of merchandise and functions primarily based on exosomes, raised €5M in Sequence A funding.
Backers included dsm-firmenich Ventures, CDP Enterprise Capital, Linfa Fund (managed by Riello Investimenti Sgr), and Maia Ventures.
The corporate intends to make use of the funds to extend manufacturing capability and provide new alternatives for superior analysis initiatives.
Based by Mariantonia Logozzi and Stefano Fais, together with Lorenzo Cilli and Valerio Carconi, and led by CEO Gabriele Campi, ExoLab Italia is a biotech startup specializing within the creation of merchandise and functions primarily based on plant-derived exosomes, extracted from natural Italian vegetables and fruit. Exosomes are vesicles able to carrying antioxidants, nutritional vitamins, proteins, and lipids particular to the plant, in addition to its nucleic acids. They’re utilized in useful actives markets, significantly within the cosmetics and dietary dietary supplements industries, in addition to within the analysis and improvement of drug supply programs, resulting from their capability to be loaded with exogenous molecules and obtain unparalleled supply effectivity.
FinSMEs
18/02/2025
